| Literature DB >> 30227873 |
Sha Tao1, Ying Qian1, Xin Wang1, Weijia Cao1, Weichao Ma1, Kequan Chen2, Pingkai Ouyang1.
Abstract
BACKGROUND: Microbial biosynthesis of natural products holds promise for preclinical studies and treating diseases. For instance, pinocembrin is a natural flavonoid with important pharmacologic characteristics and is widely used in preclinical studies. However, high yield of natural products production is often limited by the intracellular cofactor level, including adenosine triphosphate (ATP). To address this challenge, tailored modification of ATP concentration in Escherichia coli was applied in efficient pinocembrin production.Entities:
Keywords: ATP; CRISPRi; Flavonoids; Pinocembrin
Mesh:
Substances:
Year: 2018 PMID: 30227873 PMCID: PMC6142380 DOI: 10.1186/s12934-018-0995-7
Source DB: PubMed Journal: Microb Cell Fact ISSN: 1475-2859 Impact factor: 5.328
Fig. 1Metabolic pathway for pinocembrin production in E. coli. In the metabolic map, reactions from the pinocembrin pathway are shown in violet and Up-regulations are shown blue. DAHP, 3-deoxy-d-arabino-heptulosonate-7-phosphate; SAM, S-adenosylmethionine; PAL, phenylalanine ammonia lyase encoded by pal; 4CL, 4-coumaroyl-CoA ligase encoded by 4cl; CHS, chalcone synthase encoded by chs; CHI, chalcone isomerase encoded by chi
Plasmids used in this study
| Plasmid | Plasmid description | Source |
|---|---|---|
| 44249-dcas9 | P15A Replicon CmR | Addgene |
| pACYC-dcas9 | The dCas9 gene on plasmid 44249-dCas9 was inserted into the BglII and XhoI restriction sites of the pACYCDuet-1 plasmid | This study |
| pCDF303 | Trc promoter, CloE1 replicon, SmR | This study |
| pCDF303- | Plasmid is used for high intensity repression of | This study |
| pCDF303- | Plasmid is used for medium intensity repression of | This study |
| pCDF303- | Plasmid is used for low intensity repression of | This study |
| pCDF- | Plasmid is used for high intensity repression of | This study |
| pCDF- | Plasmid is used for high intensity repression of | This study |
| pCDF- | Plasmid is used for high intensity repression of | This study |
| pCDF- | Plasmid is used for high intensity repression of | This study |
| pCDF- | Plasmid is used for medium intensity repression of | This study |
| pCDF- | Plasmid is used for low intensity repression of | This study |
| pCDF- | Plasmid is used for high intensity repression of | This study |
| pCDF- | Plasmid is used for medium intensity repression of | This study |
| pCDF- | Plasmid is used for low intensity repression of | This study |
| pCDF- | Plasmid is used for high intensity repression of | This study |
| pCDF- | Plasmid is used for medium intensity repression of | This study |
| pCDF- | Plasmid is used for low intensity repression of | This study |
| pCDF- | Plasmid is used for high intensity repression of | This study |
| pCDF- | Plasmid is used for low intensity repression of | This study |
| pCDF- | Plasmid is used for medium intensity repression of | This study |
| pCDF- | Plasmid is used for medium intensity repression of | This study |
| pCDF- | Plasmid is used for low intensity repression of | This study |
| pCDF- | Plasmid is used for high intensity repression of | This study |
| pCDF- | Plasmid is used for medium intensity repression of | This study |
| pCDF- | Plasmid is used for high intensity repression of | This study |
| pCDF- | Plasmid is used for high intensity repression of | This study |
| pCDF- | Plasmid is used for high intensity repression of | This study |
| pCDF- | Plasmid is used for high intensity repression of | This study |
Strains used in this study
| Strain | Strain description | Source |
|---|---|---|
| Empty | BL21 (DE3) with pTrc-BOPAL-PA4CL, pRSF-CHS (Met) -CHI plasmid | This study |
| Control | Empty with pACYC-dCas9 plasmid | This study |
| Control with pCDF303- | This study | |
| Control with pCDF303- | This study | |
| Control with pCDF303- | This study | |
| Cri- | Control with pCDF- | This study |
| Cri- | Control with pCDF- | This study |
| Cri- | Control with pCDF- | This study |
| Cri- | Control with pCDF- | This study |
| Cri- | Control with pCDF- | This study |
| Cri- | Control with pCDF- | This study |
| Cri- | Control with pCDF- | This study |
| Cri- | Control with pCDF- | This study |
| Cri- | Control with pCDF- | This study |
| Cri- | Control with pCDF- | This study |
| Cri- | Control with pCDF- | This study |
| Cri- | Control with pCDF- | This study |
| Cri- | Control with pCDF- | This study |
| Cri- | Control with pCDF- | This study |
| Cri- | Control with pCDF- | This study |
| Cri- | Control with pCDF- | This study |
| Cri- | Control with pCDF- | This study |
| Cri- | Control with pCDF- | This study |
| Cri- | Control with pCDF- | This study |
| Cri-A | Control with pCDF- | This study |
| Cri-M | Control with pCDF- | This study |
| Cri-AM | Control with pCDF- | This study |
| Cri- | Control with pCDF- | This study |
| Cri- | Control with pCDF- | This study |
Fig. 2The effect of ATP additive on pinocembrin production. Different concentrations of ATP ranging from 0 to 6 mM was added in the medium
Fig. 3The effect of single gene high intensity repression on ATP level and product distribution. a The effect of single gene high intensity repression on ATP level; b the effect of single gene high intensity repression on pinocembrin and cinnamic acid production
Fig. 4The effect of genes different intensity repression on product distribution and ATP accumulation. a The effect of single gene medium or low intensity repression on pinocembrin and cinnamic acid production; b the effect of single gene medium or low intensity repression on ATP level; c the effect of multiple-genes inhibition on pinocembrin and cinnamic acid production
Fig. 5The effect of genes on malonyl-CoA level and product distribution. a The effect of single gene different repression on strain growth and malonyl-CoA level; b the effect of single gene different repression on pinocembrin and cinnamic acid production; c the effect of multiple-genes inhibition on pinocembrin and cinnamic acid production
Fig. 6Time-course of OD600, substrate consumption and the products during 48 h fermentation by control strains, Cri-A, Cri-M and Cri-AM. a The effect of different strains on growth; b the effect of different strains on l-phenylalanine consumption; c the effect of different strains on pinocembrin production; d the effect of different strains on cinnamic acid production
Fig. 7Time-course of ATP, ADP, the ratio of ATP to ADP and malonyl-CoA during 48 h fermentation by control strains, Cri-A, Cri-M and Cri-AM. a The effect of different strains on ATP level; b the effect of different strains on ADP level; c the effect of different strains on the ratio of ATP to ADP; d the effect of different strains on malonyl-CoA level
Fig. 8Optimization of induction conditions by Cri-AM strains. a Optimization of induction OD600; b optimization of IPTG concentration; c optimization of l-phenylalanine concentration; d the pinocembrin and cinnamic acid production of Cri-AM and Cri-AM after induction optimization